BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Cord Blood » Page 3

Cord Blood

Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.

How Stem Cell Treatments Can Ease Hip Injuries and Arthritis

February 1, 2022 By Cade Hildreth (CEO) 1 Comment

Feature | Stem Cell Treatments For Hips

In addition to the use of stem cells for the treatment of cancer and other chronic diseases, stem cell treatments for hips are being now showing great promise.

Throughout time and across the world, people have aged into delicacy, and ultimately, decline. While death is a natural part of the human condition – the end any organism can expect eventually – it sometimes comes sooner than it needs. Even when it doesn’t, decline makes life more difficult and the body less sound. This hard fact has made the possibility of stem cell treatments for hips and other parts of the body appealing. [Read more…]

Filed Under: Cord Blood

Cord Blood and Tissue Banking Market Dynamics in 2022

February 1, 2022 By Cade Hildreth (CEO) Leave a Comment

The first transplant using cord blood-derived hematopoietic stem cells was performed in October 1988. Since that year, remarkable achievements have been made in terms of research into umbilical cord blood-derived hematopoietic and progenitor cells. More than 40,000 UCB transplants (UCBTs) have been performed across different geographies of the world, in both children and adults, to treat diseases that include hematologic, metabolic, immunologic, neoplastic, and neurologic disorders. [Read more…]

Filed Under: Cell Therapy, Cord Blood

How the Cord Blood and Tissue Market is Changing

January 17, 2022 By Cade Hildreth (CEO) Leave a Comment

What Are the Benefits of Banking Cord Blood Inside The Cost Of Cord Blood Banking

The global cord blood and tissue banking market is consolidating, driven by the emergence of holding companies and aggressive M&A activity. This is creating risks for cord blood market participants, as well as new opportunities.

Serious threats to the industry include:

  • Low rates of stored cord blood utilization
  • Utilization of bone marrow and peripheral blood stem cells as alternative sources of stem cells for HSCT
  • Growing prevalence of haploidentical transplantation
  • Expensive transplant procedures, ranging from $200-300K
  • Difficulty educating Obstetricians about the future value of cellular therapies
  • Low rates of market penetration
  • Low rates of cord blood awareness among expectant parents

[Read more…]

Filed Under: Cord Blood Tagged With: cord blood, cord tissue, placental

Onk Therapeutics Secures $21.5M Series A for Cord Blood and iPSC-derived NK Cell therapies

January 17, 2022 By Cade Hildreth (CEO) Leave a Comment

ONK Therapeutics
  • $21.5M Series A financing round to advance pipeline of next-gen engineered off-the-shelf NK cell therapies
  • Funding round led by current investors Acorn Bioventures and ALSHC; joined by new investor Cormorant Asset Management
  • Financing will drive multiple pre-clinical programs through IND-enabling studies and the continued progression of a GMP manufacturing capability

[Read more…]

Filed Under: CAR-T, Cell Therapy, Cord Blood, iPS Cells

Cord Blood Banking in Latin America – Interview with James Mendez of Cryoholdco

January 16, 2022 By Cade Hildreth (CEO) Leave a Comment

In this interview with James Alexis Mendez, we discuss the market strategy of CryoHoldco, a stem cell bank holding company that is the market leader in Latin America and one of the ten largest cord blood banks in the world. James Alexis Mendez currently serves as the CFO and Board member of CryoHoldco.

Approaching 200,000 stem cell units in storage, CryoHoldco is more than 5X larger than any other stem cell bank in Latin America. CryoHoldco owns the cord blood market leaders in both Mexico and Colombia, and plans to expand into other regions of Latin America. [Read more…]

Filed Under: Cord Blood, HSCs, Interviews, MSCs Tagged With: cord blood, CryoHoldco, interview, Latin America

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 57
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97

Featured Posts

PolarityTE RMAT

PolarityTE Announces FDA RMAT Awarded to Its Designation Granted to SkinTE®

Advanced Therapy | What is a RMAT Designation (and Who Has One)?

What Is An RMAT? List of Publicly Announced RMAT Designations (64)

i-peaces-cell-manufacturing

I Peace accelerates allogeneic iPSC-derived cell therapies with a high throughput method to identify a large number of donors with specific HLA haplotypes

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.